Markets
Burlington Stores
Burlington store in Exton, Pennsylvania

Burlington surges after huge Q2 beat and raised outlook as shoppers keep bargain hunting

The off-price chain topped Wall Street’s expectations as deal hunters and brand deals fueled growth.

8/28/25 10:17AM

Burlington Stores shares soared on Thursday morning after the off-price retailer reported second-quarter results that easily beat Wall Street forecasts and raised its full-year guidance.

Adjusted earnings per share came in at $1.59, topping the Street’s estimate of $1.28. Revenue rose 10% to $2.7 billion, ahead of expectations for about $2.6 billion. Same-store sales growth of 5% lapped estimates for an increase of 1.4%.

Looking ahead: Burlington lifted its full-year sales growth outlook to 7% to 8%, up from a prior range of 6% to 8%, and raised adjusted EPS guidance to $9.19 to $9.59, from its previous forecast of $8.70 to $9.30. The midpoint of $9.39 comes in above Wall Street’s $9.24 projection.

On the earnings call, management said faster inventory turns led to fewer markdowns in the quarter, partly tied to new store openings. Executives also flagged tariffs and inflation (especially if it spreads to essentials like groceries) as key risks, adding that the company will have to be cautious about price hikes to stay focused on value. 

“We anticipate that tariffs will put significant pressure on our merchandise margin,” the company said in a statement. “But we are confident that, as long as tariffs do not increase from current levels, we can offset this pressure elsewhere in the P&L.”

Burlington has been beefing up its branded assortment with labels like Nike, Calvin Klein, and Michael Kors, making its racks more competitive with rivals like TJX and Ross. Last week, TJX shares hit an all-time high after the off-price retailer delivered knockout Q2 results and a boost to full-year guidance.

Burlington shares are now positive on the year, up 7% year to date.

More Markets

See all Markets
markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

markets

Momentum stocks reverse, weighing on US markets

Momentum stocks dragged the market lower Friday, with stocks like Palantir Technologies, SoundHound AI, Rocket Lab, Robinhood Markets, and GE Vernova continuing a recent slide.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company.)

The iShares MSCI USA Momentum Factor ETF opened 1% higher and built on those gains before reversing hard early in the session to trade 1% lower as of 11 a.m. ET.

If it closes at these levels, this fund that holds US stocks with the best risk-adjusted trailing returns will have completed a so-called “bearish engulfing candle pattern.” As the name suggests is, this is considered to be a negative technical signal that occurs when, the day after a security rises, it ends up opening above the previous day’s closing price and closes below the previous day’s opening price.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.